Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
UnicoCell Biomed Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 368.23%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for UnicoCell Biomed Co's 3-Year ROIIC % or its related term are showing as below:
TPE:6794's 3-Year ROIIC % is ranked better than 88.96% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs TPE:6794: 368.23
UnicoCell Biomed Co (TPE:6794) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
UnicoCell Biomed Co 3-Year ROIIC % Related Terms
UnicoCell Biomed Co 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6794 vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, UnicoCell Biomed Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's 3-Year ROIIC % falls into.
UnicoCell Biomed Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -130.162 (Dec. 2025) - -92.109 (Dec. 2022) )
/
( 181.224 (Dec. 2025) - 191.558 (Dec. 2022) )
=
-38.053
/
-10.334
=
368.23%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
UnicoCell Biomed Co (TPE:6794) has a 3-Year ROIIC % of 368.23 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on UnicoCell Biomed Co and its competitors. According to the industry distribution chart, UnicoCell Biomed Co ranks #146 out of 1322 companies in the Biotechnology industry, placing it in the top 11%.
Is UnicoCell Biomed Co's 3-Year ROIIC % too high?
UnicoCell Biomed Co's current 3-Year ROIIC % is 368.23. Based on the distribution chart, UnicoCell Biomed Co ranks #146 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UnicoCell Biomed Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #146 out of 1322 companies for 3-Year ROIIC %. This places UnicoCell Biomed Co in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on UnicoCell Biomed Co and its competitors. UnicoCell Biomed Co's current 3-Year ROIIC % is 368.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$102.13, compared to a current price of NT$77.70 — trading 23.9% below its estimated fair value. The current 3-Year ROIIC % is 368.23. UnicoCell Biomed Co's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current 3-Year ROIIC % is 368.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued.
The current stock price of NT$77.70 is trading 23.9% below its estimated GF Value™ of NT$102.13.
GuruFocus considers UnicoCell Biomed Co to be Modestly Undervalued.
Key valuation signals for TPE:6794:
3-Year ROIIC %: 368.23
GF Value™: NT$102.13 vs. price of NT$77.70 (23.9% below fair value)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
83GF Score
Get the complete analysis for TPE:6794
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
